The increasing and excessive use of plasma and Remdesivir for treatment is helping the Covid virus to mutate. If India does not follow evidence-based treatment, it can soon become the breeding ground for many variants of Coronavirus, Dr Raman Gangakhedkar, ex-ICMR scientist said during Covid briefings.
Must Watch: Did China Save US From Default?
The increasing use of Remdesivir and Plasma can lead to SARS-CoV-2 virus mutating and becoming stronger, ex-ICMR scientist Dr. Raman Gangakhedkar said.
He was the face of ICMR during government briefings on coronavirus last year. He told ThePrint that indiscriminate use of treatment “can help the SARS-CoV-2 virus mutate further and become stronger”.
“While on one side, the body’s own immune system puts pressure on the virus to mutate, using ill-timed treatment options, such as Remdesivir in mild disease and plasma in moderate to severe, can make the virus become stronger,” he said.
“The government should clearly communicate with doctors and hospitals to stop or rationalise the ongoing use of convalescent plasma and antiviral drug Remdesivir,” added Gangakhedkar.
MUST WATCH: The Truth About COVID-19 Revealed In EU Parliament
“With a large number of Indians exposed to the virus followed by the use of these treatment options on them, the chances of developing mutations, which may be of high significance and evade vaccine-induced immune protection, become high,” he warned.
“We could become a breeding ground for several mutants during this rapidly spreading wave if we do not adhere to evidence-based treatments.”
External Affairs Ministry thanks Gilead Sciences, a US biopharmaceutical company, for gift of over 29,000 vials of #Remdesivir that arrived in Mumbai early this morning. pic.twitter.com/MvX976m4Ud
— All India Radio News (@airnewsalerts) May 15, 2021
Not just Gangakhedkar, but many scientists and medical professionals have raised concerns over “irrational and non-scientific use of convalescent plasma” to treat COVID-19.
These experts said in a letter to Professor K. Vijay Raghavan (principal scientific advisor to the Government of India) and Dr Balram Bhargava, (Director General of ICMR) that ICMR guidelines on plasma treatment were not evidence based.
“Convalescent plasma is a very old method used as a first attempt to fight any new disease when you know nothing about a deadly infectious disease,” Dr Gangakhedkar said.
“Also, in India, we are injudiciously using the plasma which should not be given after the seventh day of Covid-19 illness.”
Ineffective therapies lead to mutations, Dr Gangakhedkar said viruses are microorganism and smart and they keep mutating. They mutate in the body of hosts, they die when hosts die.
“These viruses have error-prone reproductive enzymes and hence they develop mutations,” he said.
“The more times the virus replicates, whether through a longer survival in an immunosuppressed individual or by quickly infecting other individuals during a wave, the more is the opportunity to mutate and accumulate these mutations.”
“We challenge the virus through the selective pressure of ineffective or irrational use of antivirals or immune pressure through plasma, it will recognise the pattern and will try to change to evade those therapies”.
“Eventually, it may become a better and fit virus,” he said.
“A drug like Remdesivir is known to attack one of those enzymes, not all. This will give the virus a chance to try and produce a progeny with mutation where the drug is attacking,” he said.
“Plasma is not for moderate to severe disease whereas Remdesivir, which may reduce hospitalisation by a few days if given during moderate to severe disease, is not advised for mild disease,” he said.
“However, there is confusion and people are desperately searching for these therapies on social media channels for every patient.“
“We must think about those relatives who are running for these drugs from here to there thinking it will save their loved ones life,” the doctor added.
“They have no idea that these therapies are ineffective in certain disease stages.”
The lack of clarity of treatment can be harmful.
Earlier, India’s top health expert disclosed that the much sought after Remdesivir is not a wonder drug nor it is given either to mild or severe Covid-19 patients.
Director of AIIMS, Dr P K Singh disclosed it before Patna High Court and submitted that this drug or injection was not meant for Covid-19 patients.
Meanwhile, COVID-19 recovered patients are suffering from post viral symptoms of Mucormycosis (MM) also known as Black Fungus which is making them blind.
Heath experts say the Black Fungus is caused by the use of steroids during Covid-19 infection.
Support GreatGameIndia
when does the sleepy military stand up stoping all poisonous vaccinations and the
false insidious PCR test through the nose what is a hidden vaccination ? ? ?
Luminaries like Dr. C. R. Rao have found that India is a great population lab. The article suggests that different states or medical teams could run controlled experiments on the best therapies. I’ve not seen elsewhere that a variant could be STRONGER than the original. Thanks again!
How are they determining there’s variants of a virus that has never been isolated or sequenced?
The government should clearly communicate with doctors and hospitals to stop or rationalise the ongoing use of convalescent plasma and antiviral drug Remdesivir,” added Gangakhedkar.
The Government and Private corporations is part of the problem
If Government regulates these products you wind up with guys like founders [ Bill Gates on board of WHO] and Dr Fauci [ out sourcing illegal level4 bioweapon designer viruses to places like wuhan]
Example:chinese scientists try to find cure for Aids [ Dr Faucis funding during aids epidemic and continued past the initial epidemic].
Chinese Scientists Have Tried to Cure HIV with CRISPR Gene Editing: ‘The Genie Is out of the Bottle’
BY KASHMIRA GANDER ON 9/12/19 AT 6:05 AM EDT
Scientists in China have used the CRISPR gene-editing technique to try to cure a man of HIV, in what one expert called an “important step” forwards in treating disease.
1-Carl June, professor of immunotherapy at the University of Pennsylvania wrote an editorial in the New England Journal of Medicine critiquing the work.
He told the Associated Press: “They need to approach 90 percent or more, I think, to actually have a chance of curing HIV.” It was positive that the scientists did not make a “Frankenstein cell” that would affect other genes instead of the intended target, he told the news agency
……June told the Associated Press the approach appeared to be safe and precise, and it raised no ethical concerns.
2-“In the NEJM editorial, he argued it was “striking” how quickly the team went from a proof of concept in animals to a trial in a human in two years. Such a process would take five years in the U.S., he said.
Bill Gates was talking to President Trump in the Oval Office last month when the conversation turned to the notion of a universal flu vaccine .
You should associate yourself with American innovation. Wouldn’t you love to have the universal flu vaccine be something that really got kicked off and energized by you?” Gates recalled asking Trump.
That larger package would include wealthy nations like the U.S. mounting an Operation Warp Speed-style effort to invest in manufacturing in low-income countries, he said, using their vast financial resources to actually produce vaccine doses rather than solely targeting patents.
TOPLINE
As Covid-19 cases continue to increase in developing countries, the Bill & Melinda Gates Foundation has donated $150 million to the world’s largest vaccine manufacturer, Serum Institute of India, to provide up to 100 million Covid-19 vaccine doses to poorer nations priced at less than $3 a dose.
The money will allow Serum Institute of India to begin manufacturing vaccines from its partners, biopharmaceutical companies AstraZeneca and Novavax, so they will be readily available if they are approved, the institute said in a statement..
Note: Jeremy Farrar head of Wellcome Trust in london
Jeremy Farrar (@JeremyFarrar) Tweeted:
Potentially really important moment in global public health-must be celebrated, everyone involved in Wuhan, in China & beyond acknowledged, thanked & get all the credit. Sharing of data good for public health, great for those who did the work. Just needs those incentives & trust
U.S. Pat. No. 10,130,701. (Nov. 20, 2018). CORONAVIRUS. Assignee: THE PIRBRIGHT INSTITUTE (Woking, Pirbright, Great Britain), funded by Wellcome Trust, DARPA, Bill & Melinda Gates Foundation, EU. U.S. Patent Office
The web of entanglement of government agencies funded with public monies and private corporations has major ethical issues and bias regulatory oversight.
The merger of these two endeavours was started by Victor Rothschild in his 1971 report which calls them science brokers .
“1971, (Lord) Victor Rothschild, reported to Government on “The Organisation and Management of Government R&D” and how government could become (in his words) a customer for research contracted…
In 1971, (Lord) Victor Rothschild, reported to Government on “The Organisation and Management of Government R&D” and how government could become (in his words) a customer for research contracted from the Research Councils and other sources. Rothschild’s thinking implied that management of R&D by “customer” Departments would bring an understanding of research outputs. He proposed the transfer of applied science funds from Research Councils to Government Departments, providing each with a Chief Scientist as proxy customer for research to be commissioned on a “customer/contractor” basis. The Government largely adopted his proposals in 1972 and implemented them in 1974. The Rothschild reforms and the upheavals they brought were controversial at the time, though now in some instances, reversed and otherwise either forgotten or buried in unconscious assumptions. However, the Rothschild framework still underpins important assumptions about Departmental relationships with the science community, which in my view adversely affected the access of Government to expert advice. From the viewpoint of a participant in Government R&D management through this period, I explore the immediate response and the post-1980 history of the Rothschild reforms, discuss the way in which research commissioning became such a heavy task as to impede analysis and advice delivery, and consider alternative approaches, such as the “science broker” model. This article is published as part of a collection on scientific advice to governments.
Well, that is actually incorrect, by a long shot. It was first sequenced on 24 January 2020 at Institut Pasteur. The “information” that is has never been isolated or sequenced is just false news being posted and reposted across social media, then turned into “articles” by people who either don’t know better or have less-than-honest intent, using circular reporting to “confirm” their story.
Post above was a reply to @lynnthoma, BTW.